perhexiline has been researched along with Left Ventricular Dysfunction in 3 studies
Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perhexiline has become a "last-line" agent for refractory angina as a result of complex pharmacokinetics and potential toxicity." | 5.37 | Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline. ( Averbuj, P; Chik, W; Horowitz, JD; Ling, LH; Morris, RG; Ngo, DT; Pati, PK; Sallustio, BC; Sverdlov, AL, 2011) |
| "Perhexiline has become a "last-line" agent for refractory angina as a result of complex pharmacokinetics and potential toxicity." | 1.37 | Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline. ( Averbuj, P; Chik, W; Horowitz, JD; Ling, LH; Morris, RG; Ngo, DT; Pati, PK; Sallustio, BC; Sverdlov, AL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansal, M | 1 |
| Chan, J | 1 |
| Leano, R | 1 |
| Pillans, P | 1 |
| Horowitz, J | 1 |
| Marwick, TH | 1 |
| Abozguia, K | 1 |
| Elliott, P | 1 |
| McKenna, W | 1 |
| Phan, TT | 1 |
| Nallur-Shivu, G | 1 |
| Ahmed, I | 1 |
| Maher, AR | 1 |
| Kaur, K | 1 |
| Taylor, J | 1 |
| Henning, A | 1 |
| Ashrafian, H | 1 |
| Watkins, H | 1 |
| Frenneaux, M | 1 |
| Ling, LH | 1 |
| Chik, W | 1 |
| Averbuj, P | 1 |
| Pati, PK | 1 |
| Sverdlov, AL | 1 |
| Ngo, DT | 1 |
| Morris, RG | 1 |
| Sallustio, BC | 1 |
| Horowitz, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)[NCT00500552] | Phase 2 | 44 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for perhexiline and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction.
Topics: Aged; Cardiotonic Agents; Cardiovascular Agents; Dobutamine; Echocardiography; Exercise Test; Female | 2010 |
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
Topics: Blood Glucose; Cardiomyopathy, Hypertrophic; Double-Blind Method; Energy Metabolism; Exercise Tolera | 2010 |
1 other study available for perhexiline and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
Topics: Aged; Aged, 80 and over; Aging; Angina Pectoris; Body Weight; Cardiovascular Agents; Creatinine; Hum | 2011 |